SLC16A1 and neoplasm: Moreover, no antibodies or small molecule inhibitors have been seen to simultaneously regulate CD44, integrins, FAK, and MCT1 in the same manner as h4#147D, suggesting that h4#147D exhibits strong antitumor activity with complete tumor regression via unique mechanisms of reducing CD147-binding proteins and activating stress-responsivesignal-mediated cell death.